Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

R&D Execs Paint Bleak Picture Of Industry Productivity: $1.4 Bil. Per NME

Executive Summary

Pharmaceutical R&D execs estimate the cost of drug development to be $1.4 bil. per new molecular entity, Wyeth R&D President Robert Ruffolo, PhD, told an IBC conference in Boston Aug. 12
Advertisement

Related Content

Levitra Is Big News On Wall Street, But Rx Firms Ask Investors To Think Small
Levitra Is Big News On Wall Street, But Rx Firms Ask Investors To Think Small
R&D Cost Estimate Should Be Studied By FDA, Rep. Brown Tells Commissioner
R&D Cost Estimate Should Be Studied By FDA, Rep. Brown Tells Commissioner
Abbott Hospital Products Spin-Off Will Free Up $500 Mil. For Rx Spending
Abbott Hospital Products Spin-Off Will Free Up $500 Mil. For Rx Spending
Abbott To Focus On Higher-Margin Drug Products, Spins Off Hospital Division
Abbott Rx For R&D Includes Tandem Drug/Biologic Development
R&D Cost Increase May Reflect Comparative Trials; Can Biotech Keep Up?
R&D Cost Increase May Reflect Comparative Trials; Can Biotech Keep Up?
Advertisement
UsernamePublicRestriction

Register

PS042336

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel